Encala is indicated for adults and children older than 1 who have started eating toddler or family table food. According to a company press release, the therapy will be commercially available as 15-serving pouches in November. Single-serving sticks for on-the-go consumption will be available in January.
Digestive issues occur in up to 90% of CF patients and they often are linked to mucus accumulation in the pancreas. The mucus blocks the release of enzymes needed for digestion, causing pancreatic insufficiency. The resulting poor nutrient and fat absorption can cause developmental problems, low weight, and chronic malnutrition. Insufficient caloric absorption also accelerates progression of lung disease in CF patients.
Pancreatic enzyme replacement therapy (PERT) temporarily replaces the missing enzymes. Although it often is prescribed in cases of pancreatic insufficiency, it can improve fat absorption to only a limited degree.
Encala is a plant-based, non-GMO (genetically modified organism), gluten-free, and flavorless powder. It provides various kinds of easily-absorbed fats and offers an alternative to other less absorbable fats typically derived from palm, coconut or vegetable oils found in most nutritional supplements.
Encala’s fats are formulated to be easily absorbed without the need for enzyme replacement or digestion. Encala’s fats also help patients absorb other fat-soluble vitamins — those that combine well with fats — found in their diet.